An interventional study of Super High-flux dialyzer (Elisio 19HDx) and High-flux dialyzer (Elisio 19H) in The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD, End Stage Kidney Disease (ESRD) and Sepsis, sponsored by Navamindradhiraj University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Navamindradhiraj University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Kidney Failure, Chronic with a site in Thailand — 4 open to participants now, 5 under way, 1 of them phase 3. Kidney Failure, Chronic · Thailand.
Among the 29 studies in Kidney Failure, Chronic with a site in Thailand, this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 27th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →4 of the 29 studies in Kidney Failure, Chronic with a site in Thailand are open now. Recruiting first, the newest first:
King Chulalongkorn Memorial Hospital · Sites in Thailand
Ages 18–80
CSL Behring · Sites in Thailand, United States, Argentina and 32 more countries
Ages 18+
The University of Queensland · Sites in Thailand, Australia, Brazil and 6 more countries
Ages 18+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 7
First in 2004; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 202 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 130 across the 24 interventional studies, 152 across the 5 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 29 have an industry lead sponsor. The 10 most frequent:
Navamindradhiraj University is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Navamindradhiraj University has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Kidney Failure, Chronic with a site in Thailand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06700876Mahidol UniversityEvaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Kidney Failure, Chronic with a site in Thailand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.
Sepsis in people who have ESKD is the risk of developing poor outcome. Cytokines play a role in the process of sepsis and cause the worsening clinical outcome despite definitive antibiotic treatment. Superhigh-flux dialyzer has a larger molecular weight cut off (MWCO) clearance, include cytokine, could contribute to improved sepsis management in individuals with ESKD. This study is conducted to prove the efficacy of super high-flux dialyzer comparing with high-flux dialyzer in case of mortality reduction for regular hemodialysis ESKD patients.
Method This study is an open label single center randomized control trial. We randomized ESKD patients who have sepsis condition with high interleukin-6 (IL-6 > 50 pg/ml).
The participants were allocated to super high-flux dialyzer group and high flux dialyzer group, stratified with diabetes, vascular access, and septic shock.
We excluded; patient who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who closed and patient who expected to pass away within the 24 hours. We aim to enroll total 202 participants; divided equally in each arm. According to our protocol, non reused super high-flux dialyzer and high-flux dialyzer are used in the same assigned patient in first week without crossing over. The standard of care of sepsis and antibiotic are provided in both groups without intervening of researcher and our protocol. The primary endpoint is 28 days of mortality. The secondary outcome include cardiovascular death, rate reduction of IL-6 after dialysis, days of hospitalization, ventilator free days and complication of dialysis are also monitored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients received dialysis with Superhigh-flux dialyzer
Device: Super High-flux dialyzer (Elisio 19HDx)
Patients received dialysis with High-flux dialyzer
Device: High-flux dialyzer (Elisio 19H)
Dialysis with Super High-flux dialyzer for intervention group
Dialysis with High-flux dialyzer for control group
Comparing the reduction of all cause death at 28 days
Comparing the efficacy to reduce all cause death at 28 days between Super High-flux dialyzer with High-flux dialyzer in ESKD with sepsis
Time frame: 28 days
Comparing the difference of blood level of IL-6, ESR, CRP and albumin, before and after of the first dialysis session, in each group.
Time frame: 7 days
The duration of inotrope weaning
Time frame: 14 days
The duration of hospitalization
Time frame: 28 days
Ventilator free days
Time frame: 28 days
The incidence of intradialytic hypotension
Time frame: 28 days
The incidence rate of complication of dialyzer in each group
The incidence rate of complication of dialyzer; allergic reaction, clotting of dialyzer etc.
Time frame: 28 days
The adequacy profile of dialysis in both groups
Time frame: 7 days
Plan to share: Undecided
Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 23 months is close to that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Navamindradhiraj University